Mechanisms involved in the antiplatelet activity of Staphylococcus aureus lipoteichoic acid in human platelets

Thromb Haemost. 2000 May;83(5):777-84.

Abstract

In this study, gram-positive Staphylococcus aureus lipoteichoic acid (LTA) dose-dependently (0.1-1.0 microg/ml) and time-dependently (10-60 min) inhibited platelet aggregation in human platelets stimulated by agonists. LTA also dose-dependently inhibited phosphoinositide breakdown and intracellular Ca+2 mobilization in human platelets stimulated by collagen. LTA (0.5 and 1.0 microg/ml) also significantly inhibited thromboxane A2 formation stimulated by collagen in human platelets. Moreover, LTA (0.1-1.0 microg/ml) dose-dependently decreased the fluorescence of platelet membranes tagged with diphenylhexatrience. Rapid phosphorylation of a platelet protein of Mr. 47,000 (P47), a marker of protein kinase C activation, was triggered by PDBu (30 nM). This phosphorylation was markedly inhibited by LTA (0.5 and 1.0 microg/ml) within a 10-min incubation period. These results indicate that the antiplatelet activity of LTA may be involved in the following pathways: LTA's effects may initially be due to induction of conformational changes in the platelet membrane, leading to a change in the activity of phospholipase C, and subsequent inhibition of phosphoinositide breakdown and thromboxane A2 formation, thereby leading to inhibition of both intracellular Ca+2 mobilization and phosphorylation of P47 protein. Therefore, LTA-mediated alteration of platelet function may contribute to bleeding diathesis in gram-positive septicemic and endotoxemic patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Calcium Signaling / drug effects
  • Cell Membrane / drug effects
  • Cell Membrane / ultrastructure
  • Collagen / pharmacology
  • Cytosol / enzymology
  • Dose-Response Relationship, Drug
  • Endotoxemia / blood
  • Endotoxemia / complications
  • Endotoxemia / microbiology
  • Enzyme Activation / drug effects
  • Gram-Negative Bacterial Infections / blood
  • Gram-Negative Bacterial Infections / complications
  • Gram-Positive Bacterial Infections / blood
  • Gram-Positive Bacterial Infections / complications
  • Hemorrhagic Disorders / etiology
  • Humans
  • L-Lactate Dehydrogenase / analysis
  • Lipopolysaccharides / pharmacology*
  • Membrane Fluidity / drug effects
  • Membrane Lipids / metabolism
  • Nitric Oxide Synthase / biosynthesis
  • Nitric Oxide Synthase / genetics
  • Nitric Oxide Synthase Type II
  • Peptides / pharmacology
  • Phorbol 12,13-Dibutyrate / pharmacology
  • Phosphatidylinositols / metabolism
  • Phosphorylation / drug effects
  • Platelet Aggregation / drug effects*
  • Platelet Aggregation Inhibitors / pharmacology*
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
  • Protein Kinase C / metabolism
  • Protein Processing, Post-Translational / drug effects
  • Sepsis / blood
  • Sepsis / complications
  • Sepsis / microbiology
  • Shock, Septic / blood
  • Shock, Septic / complications
  • Staphylococcus aureus / chemistry*
  • Teichoic Acids / pharmacology*
  • Thromboxane A2 / biosynthesis
  • Thromboxane B2 / biosynthesis

Substances

  • Lipopolysaccharides
  • Membrane Lipids
  • Peptides
  • Phosphatidylinositols
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Teichoic Acids
  • triflavin
  • Phorbol 12,13-Dibutyrate
  • Thromboxane B2
  • lipoteichoic acid
  • Thromboxane A2
  • Collagen
  • L-Lactate Dehydrogenase
  • NOS2 protein, human
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type II
  • Protein Kinase C